echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > FDA approves DrugsMD company Bijuva for treatment of vascular movement disorders in menopausal patients

    FDA approves DrugsMD company Bijuva for treatment of vascular movement disorders in menopausal patients

    • Last Update: 2020-06-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    about 43 million women in the U.Sare in menopause, and as the ovaries stop producing estrogen, estrogen levels in the blood circulation drop, leading to VMS, often characterized by hot flashes and night sweatsToday,
    TheFDA(approved by the u.SFDA) to treat vasomotor movement disorders (vasomotor symptoms, VMS) in menopausal patients, usually characterized by hot flashes and night sweatsabout Bijuva
    Bijuva is a fixed-dose compounddrug(capsule) consisting of 1 mg of estrogen and 100 mg of progesteroneThis is the first FDA-approved bio-identical combination hormone replacement therapy to treat menopausal symptoms in menopausal women due to decreased hormone levels in their own hormonesthe study
    more than 700 menopausal women with VMS received Bijuva or placebo treatment in a randomized double-blind, placebo-controlled, multicenter phase 3 clinicaltrial(of which VMS was conducted)results show that Bijuva is able to statistically significantly reduce the frequency and severity of VMS in patients and demonstrate good safety   Bijuva is expected to be available in the second quarter of 2019, and we hope it will reduce the problems of VMS for menopausal women
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.